8-K 1 k8_7-2001.htm Form 8-K







UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 

WASHINGTON, D.C. 20549
 

Form 8-K
 

CURRENT REPORT
 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 

Date of Report:
July 16, 2001
Date of earliest event reported:
July 16, 2001
 

------
 

PFIZER INC.
(Exact name of registrant as specified in its charter)
 

001-03619
(Commission File Number)
 

DELAWARE
(State of Incorporation)

13-5315170
(I.R.S. Employer Identification No.)
 

235 East 42nd Street, New York, New York 10017
(Address of principal executive offices)
 

(212) 573-2323
(Registrant's telephone number)

 

Item 5.    Other Events.

On January 1, 2001, Pfizer Inc. (the Company) adopted the provisions of the Emerging Issues Task Force Issue No. 00-14, Accounting for Certain Sales Incentives, which addresses the income statement classification of certain sales incentives. Additionally, the Company recorded accounting adjustments pertaining to the harmonization of the Company's and the former Warner-Lambert Company's accounting methodologies related to royalty expenses and certain other sales incentives. As a result, the Company reclassified the cost of certain sales incentives between Selling, informational and administrative expenses and Revenues and royalty expenses between Other income-net and Cost of sales on the consolidated statements of operations. These reclassifications have no effect on net income.

The Company is filing unaudited restated consolidated statements of operations for the quarters ended April 2, 2000, July 2, 2000, October 1, 2000 and for the quarter and year ended December 31, 2000 which are included in Exhibit 99.1 to this Form 8-K and are incorporated by reference.

Item 7.    Exhibits.

Exhibit

  

Description

99.1

  

Unaudited restated consolidated statements of operations for the quarters ended April 2, 2000, July 2, 2000, October 1, 2000 and for the quarter and year ended December 31, 2000.

Signature

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
 

             PFIZER INC.            
 

(Registrant)
   
   

Date: July 16, 2001

      /s/ Margaret M. Foran        

   
 

Margaret M. Foran
Title: Vice President - Corporate Governance

 

EXHIBIT INDEX

99.1

  

Unaudited restated consolidated statements of operations for the quarters ended April 2, 2000, July 2, 2000, October 1, 2000 and for the quarter and year ended December 31, 2000.

 

Exhibit 99.1

PFIZER INC. AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 

             Quarter*            

  

(millions, except per share data)

First 

Second 

Third 

Fourth 

Year* 

2000

          

Revenues

$7,161 

$6,989 

$7,158 

$8,047 

$29,355 
           

Costs and expenses:

          

 Cost of sales

1,236 

1,180 

1,221 

1,371 

5,007 

 Selling, informational and
  administrative expenses

2,733 

2,824 

2,650 

3,017 

11,223 

 Research and development expenses

1,061 

1,086 

1,025 

1,264 

4,435 

 Merger related costs

1,838 

431 

505 

483 

3,257 

 Other income-net

  (117)

  (199)

   (28)

    (7)

  (348)

Income from continuing operations
 before provision for taxes on
 income and minority interests

410 

1,667 

1,785 

1,919 

5,781 

Provision for taxes on income

613 

513 

421 

500 

2,049 

Minority interests

     1 

     4 

     3 

     7 

    14 

Income/(loss) from continuing
 operations

(204)

1,150 

1,361 

1,412 

3,718 

Discontinued operations-net of
 tax

    -- 

    -- 

    -- 

     8 

     8 

Net income/(loss)

$ (204)
====== 

$1,150 
====== 

$1,361 
====== 

$1,420 
====== 

$3,726 
====== 
           

Earnings/(loss)per common share--
basic

          

 Income/(loss)from continuing
  operations

$ (.03)
====== 

$  .18 
====== 

$  .22 
====== 

$  .23 
====== 

$  .60 
====== 

 Net income/(loss)

$ (.03)
====== 

$  .18 
====== 

$  .22 
====== 

$  .23 
====== 

$  .60 
====== 
           

Earnings/(loss) per common share--
diluted

          

 Income/(loss)from continuing
  operations


$ (.03)
====== 

$  .18 
====== 

$  .21 
====== 

$  .23 
====== 

$  .59 
====== 

 Net income/(loss)

$ (.03)
====== 

$  .18 
====== 

$  .21 
====== 

$  .23 
====== 

$  .59 
====== 
           

Weighted average shares--basic

6,152 
====== 

6,217 
====== 

6,228 
====== 

6,237 
====== 

6,210 
====== 

Weighted average shares--diluted

6,152 
====== 

6,369 
====== 

6,371 
====== 

6,384 
====== 

6,368 
====== 
           

Cash dividends paid per common share

$  .09 
====== 

$  .09 
====== 

$  .09 
====== 

$  .09 
====== 

$  .36 
====== 
  1. The above financial statements present the first quarter ended April 2, 2000, the second quarter ended July 2, 2000, the third quarter ended October 1, 2000 and the fourth quarter and year ended December 31, 2000. Subsidiaries operating outside the United States are included on the basis of a one month lag.
  2. In June 2000, the Company completed its merger with Warner-Lambert Company which was accounted for as a pooling of interests. As a result, Pfizer restated its financial data prior to the merger to include the results of operations of Warner-Lambert.
  3. On January 1, 2001, Pfizer Inc. (the Company) adopted the provisions of the Emerging Issues Task Force Issue No. 00-14, Accounting for Certain Sales Incentives, which addresses the income statement classification of certain sales incentives. Additionally, the Company recorded accounting adjustments pertaining to the harmonization of the Company's and the former Warner-Lambert Company's accounting methodologies related to royalty expenses and certain other sales incentives. As a result, the Company reclassified the cost of certain sales incentives between Selling, informational and administrative expenses and Revenues and royalty expenses between Other income-net and Cost of sales on the consolidated statements of operations. These reclassifications have no effect on net income.

*   Certain amounts may reflect rounding adjustments.